Targeting Hepatic Glucokinase in Type 2 Diabetes Weighing the Benefits and Risks

被引：54
|
作者：
Agius, Loranne [1 ]
机构：
[1] Univ Newcastle, Sch Med, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England
来源：
DIABETES | 2009年 / 58卷 / 01期
关键词：
REGULATORY PROTEIN; GLUCOSE-HOMEOSTASIS; GLYCOGEN-METABOLISM; TRIGLYCERIDE LEVELS; FASTING GLUCOSE; FATTY RATS; LIVER; ACTIVATORS; DEFECT; LOCI;
D O I：
10.2337/db08-1470
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：18 / 20
页数：3
相关论文
共 50 条
  • [1] Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
    Lupsa, Beatrice C.
    Inzucchi, Silvio E.
    DIABETOLOGIA, 2018, 61 (10) : 2118 - 2125
  • [2] Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
    Beatrice C. Lupsa
    Silvio E. Inzucchi
    Diabetologia, 2018, 61 : 2118 - 2125
  • [3] Decreased expression of hepatic glucokinase in type 2 diabetes
    Haeusler, Rebecca A.
    Camastra, Stefania
    Astiarraga, Brenno
    Nannipieri, Monica
    Anselmino, Marco
    Ferrannini, Ele
    MOLECULAR METABOLISM, 2015, 4 (03): : 222 - 226
  • [4] Targeting human Glucokinase for the treatment of type 2 diabetes: an overview of allosteric Glucokinase activators
    Sharma, Prateek
    Singh, Sukhbir
    Sharma, Neelam
    Singla, Deepak
    Guarve, Kumar
    Grewal, Ajmer Singh
    JOURNAL OF DIABETES AND METABOLIC DISORDERS, 2022, 21 (01) : 1129 - 1137
  • [5] Targeting human Glucokinase for the treatment of type 2 diabetes: an overview of allosteric Glucokinase activators
    Prateek Sharma
    Sukhbir Singh
    Neelam Sharma
    Deepak Singla
    Kumar Guarve
    Ajmer Singh Grewal
    Journal of Diabetes & Metabolic Disorders, 2022, 21 : 1129 - 1137
  • [6] Weighing risks and benefits
    Hansson, SO
    TOPOI-AN INTERNATIONAL REVIEW OF PHILOSOPHY, 2004, 23 (02): : 145 - 152
  • [7] Weighing Risks and Benefits
    Sven Ove hansson
    Topoi, 2004, 23 (2) : 145 - 152
  • [8] Weighing benefits and risks
    Isobel Barry
    Nature Reviews Cancer, 2008, 8 (7) : 484 - 484
  • [9] Targeting glucokinase activation for the treatment of type 2 diabetes - A status review
    Sarabu, R
    Grimsby, J
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2005, 8 (05) : 631 - 637
  • [10] Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator
    Vella, Adrian
    Freeman, Jennifer L. R.
    Dunn, Imogene
    Keller, Kit
    Buse, John B.
    Valcarce, Carmen
    SCIENCE TRANSLATIONAL MEDICINE, 2019, 11 (475)
12345